50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura

Monday, December 8, 2008: 11:00 AM-12:30 PM

3007-3009-3011 - West (Moscone Center)

Moderators:

Alan D Michelson and Alan Lazarus, PhD

11:00 AM

Elevated Vanin1 and Advillin Expression Is Associated with Progression to Chronic ITP in Children

Bing Zhang, MD, MS¹^*, Ruchira Sood, PhD¹, Carol Jones¹^*, Wendy Wong, MD², Michael Jeng, MD³ and James L. Zehnder, MD⁴

¹Pathology, Stanford University, School of Medicine, Palo Alto, CA
²Dept. of Pediatric Hem./Onc., Stanford University, Palo Alto, CA
³Ped. Hem./Onc., Stanford Univ. School of Medicine, Palo Alto, CA
⁴Stanford Univ. Med. Ctr., Stanford, CA

11:15 AM

398

Role of Molecular Mimickry of Hepatitis C Virus (HCV) Protein with Platelet GPIIIa in Hepatitis C-Related Immunologic Thrombocytopenia

Wei Zhang¹^*, Michael A. Nardi, MS², William Borkowsky³^* and Simon Karpatkin¹

¹Medicine/Hematology, NYU School of Medicine, New York, NY
²Pediatric Hematology, NYU School of Medicine, New York, NY
³Pediatrics Infectious Diseases, NYU School of Medicine, New York, NY

11:30 AM

399

Antibody- and Cell-Mediated Immune Thrombocytopenia Are Differentially Sensitive to Intravenous Gammaglobulin Therapy

Leola Chow, PhD¹^*, Michael Kim, BSc²^*, Edwin R. Speck, BRT²^*, Rukhsana Aslam, PhD²^*, Michelle Lee Webster, MSc²^*, Pingguo Chen, PhD²^*, Heyu Ni, MD, PhD²^*, John Freedman, MD²^* and John W. Semple, PhD²

¹St. Michael's Hospital, Toronto, ON, Canada
²St. Michael's Hospital

11:45 AM

400

Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double-Blind, Placebo-Controlled Study (RAISE)

Gregory Cheng¹^*, Mansoor N Saleh²^*, James B Bussel³, Claus Marcher⁴^*, Sandra Vasey⁵^*, Bhabita Mayer⁶^*, Manuel Aivado⁵^*, Michael Arning⁵^* and Nicole L. Stone⁵^*

¹Chinese University of Hong Kong, Shatin, NT, Hong Kong
²Georgia Cancer Specialists, Atlanta, GA
³Weill-Cornell Medical College of Cornell University, New York, NY
⁴Department of Hematology X, Odense University Hospital, Odense, Denmark
⁵GlaxoSmithKline, Collegeville, PA
⁶GlaxoSmithKline, Stockley Park, United Kingdom

12:00 PM

401

Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study

Mansoor N Saleh¹^*, James B Bussel², Gregory Cheng³^*, Balkis Meddeb⁴^*, Paul M Burgess⁵^*, Maria E De Obaldia⁶^*, Nicole L Stone⁶^* and Manuel Aivado⁶^*

¹Georgia Cancer Specialists, Atlanta, GA
²Weill-Cornell Medical College of Cornell University, New York, NY
³Chinese University of Hong Kong, Shatin, NT, Hong Kong
⁴Hôpital La Rabta, Tunis, Tunisia
⁵GlaxoSmithKline, Stockley Park, United Kingdom
⁶GlaxoSmithKline, Collegeville, PA

12:15 PM

402

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil¹^*, James B Bussel, MD², Adrian Newland, MD, FRCP³, Joost TM de Wolf, MD⁴^*, Troy Guthrie, MD⁵^*, Jeffrey Wasser, MD⁶, Lara Gehl⁷^*, Kun Nie, PhD⁷^* and Dietmar Berger, MD, PhD⁷

¹Massachusetts General Hospital, Boston, MA
²New York Presbyterian Hospital, Departments of Pediatrics and Medicine, Division of Hematology, New York, NY
³Department of Haematology, The Royal London Hospital, London, United Kingdom
⁴University Medical Center Groningen, Groningen, Netherlands
⁵Baptist Cancer Institute/University of Florida, Jacksonville, FL
⁶DeQuattro Community Cancer Center, Manchester, CT
⁷Amgen Inc., Thousand Oaks, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

311.O3.6 Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura